Leishmania major: Targeting IL-4 in successful immunomodulation of murine infection

Experimental Parasitology

Volumn 84, Issue 2, 1996, Pages 214-222

  Wakil, Adil E ^a   Wang, Zhi E N ^a   Locksley, Richard M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 4; LEISHMANIA VACCINE; RECOMBINANT INTERLEUKIN 12;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG TARGETING; FEMALE; IMMUNE RESPONSE; IMMUNOMODULATION; LEISHMANIA MAJOR; LEISHMANIASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINATION;

ANIMALIA; LEISHMANIA MAJOR; MAMMALIA; MURINAE;

EID: 0030297830     PISSN: 00144894     EISSN: None     Source Type: Journal    
DOI: 10.1006/expr.1996.0107     Document Type: Article

References (36)

1. AFONSO, L. C., SCHARTON, T. M., VIEIRA, L. Q., WYSOCKA, M., TRINCHIERI, G., AND SCOTT, P. 1994. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 263, 235-237.
2. AMIGORENA, S., DRAKE, J. R., WEBSTER, P., AND MELLMAN, I. 1994. Transient accumulation of new class II MHC molecules in a novel endocytic compartment in B lymphocytes. Nature 369, 113-120.
3. BARRY, M. A., LAI, W. C., AND JOHNSTON, S. A. 1995. Protection against mycoplasma infection using expression-library immunization. Nature 377, 632-635.
4. BEHFOROUZ, N. C., WENGER, C. D., AND MATHISON, B. X. 1986. Prophylactic treatment of BALB/c mice with cyclosporine A and its analog B-5-49 enhances resistance to Leishmania major. Journal of Immunology 136, 3067-3075.
5. BELOSEVIC, M., FINBLOOM, D. S., VAN DER MEIDE, P. H., SLAYTER, M. V., AND NACY, C. A. 1989. Administration of monoclonal anti-IFN-gamma antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major. Journal of Immunology 143, 266-274.
6. CORRY, D. B., REINER, S. L., LINSLEY, P. S., AND LOCKSLEY, R. M. 1994. Differential effects of blockade of CD28-B7 in the development of Th1 or Th2 effector cells in experimental leishmaniasis. Journal of Immunology 153, 414-2148.
7. CORRY, D. B., FOLKESSON, H. G., WARNOCK, M. L., ERLE, D. J., MATTHAY, M. A., WIENER-KRONISH, J. R., AND LOCKSLEY, R. M. 1996. Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity. Journal of Experimental Medicine 183, 109-117.
8. DE WAAL MALEFYT, R., FIGDOR, C. G., HUIJBENS, R., MOHAN-PETERSON, S., BENNETT, B., CULPEPPER, J., DANG, W., ZURAWSKI, G., AND DE VRIES, J. E. 1993. Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-gamma or IL-10. Journal of Immunology 151, 6370-6381.
9. GESSNER, A., SCHROPPEL, K., WILL, A., ENSSLE, K. H., LAUEFER, L., AND ROLLINGHOFF, M. 1994. Recombinant soluble interleukin-4 (IL-4) receptor acts as an antagonist of IL-4 in murine cutaneous leishmaniasis. Infection and Immunity 62, 4112-4117.
10. GREEN, S. J., MELTZER, M. S., HIBBS, J. B., JR., AND NACY, C. A. 1990. Activated macrophages destroy intracellular Leishmania major amastigotes by an L-arginine-dependent killing mechanism. Journal of Immunology 144, 278-283.
11. + lymphocytes in vivo during healing and progressive murine leishmaniasis. Proceedings of the National Academy of Sciences USA 88, 7011-7015.
12. HEINZEL, F. P., RERKO, R. M., HATAM, F., AND LOCKSLEY, R. M. 1993a. IL-2 is necessary for the progression of leishmaniasis in susceptible murine hosts. Journal of Immunology 150, 3924-3931.
13. HEINZEL, F. P., SCHOENHAUT, D. S., RERKO, R. M., ROSSER, L. E., AND GATELY, M. K. 1993b. Recombinant interleukin 12 cures mice infected with Leishmania major. Journal of Experimental Medicine 111, 1505-1509.
14. HOWARD, J. G., HALE, C., AND CHAN-LIEW, W. L. 1980a. Immunological regulation of experimental cutaneous leishmaniasis. 1. Immunogenetic aspects of susceptibility to Leishmania tropica in mice. Parasite Immunology 2, 303-314.
15. HOWARD, J. G., HALE, C., AND LIEW, F. Y. 1980b. Immunological regulation of experimental cutaneous leishmaniasis. III. Nature and significance of specific suppression of cell-mediated immunity in mice highly susceptible to Leishmania tropica. Journal of Experimental Medicine 152, 594-607.
16. HOWARD, J. G., HALE, C., AND LIEW, F. Y. 1981. Immunological regulation of experimental cutaneous leishmaniasis. IV. Prophylactic effect of sublethal irradiation as a result of abrogation of suppressor T cell generation in mice genetically susceptible to Leishmania tropica. Journal of Experimental Medicine 153, 557.
17. LANG, T., HELLIO, R., KAYE, P. M., AND ANTOINE, J. C. 1994. Leishmania donovani-infected macrophages: Characterization of the parasitophorous vacuole and potential role of this organelle in antigen presentation. Journal of Cell Science 107, 2137-2150.
18. LIEW, F. Y., MILLOTT, S., PARKINSON, C., PALMER, R. M., AND MONCADA, S. 1990. Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. Journal of Immunology 144, 4794-4797.
19. LOCKSLEY, R. M., REINER, S. L., HATAM, F., LITTMAN, D. R., AND KILLEEN, N. 1993. Helper T cells without CD4: Control of leishmaniasis in CD4-deficient mice. Science 261, 1448-1451.
20. MOUGNEAU, F., ALTARE, F., WAKIL, A. F., ZHENG, S., COPPOLA, T., WANG, Z. E., WALDMANN, R., LOCKSLEY, R. M., AND GLAICHENHAUS, N. 1995. Expression cloning of a protective Leishmania antigen. Science 268, 563-566.
21. NEER, E. J., SCHMIDT, C. J., NAMBUDRIPAD, R., AND SMITH, T. E. 1994. The ancient regulatory-protein family of WD-repeat proteins. Nature 371, 297-300.
22. NOBEN-TRAUTH, N., KROPF, P., AND MULLER, I. 1996. Susceptibility to Leishmania major infection in interleukin-4-deficient mice. Science 271, 987-990.
23. PETERS, B. S., FISH, D., GOLDEN, R., EVANS, D. A., BRYCESON, A. D., AND PINCHING, A. J. 1990. Visceral leishmaniasis in HIV infection and AIDS: Clinical features and response to therapy. Quarterly Journal of Medicine 77, 1101-1111.
24. PIERRE, P., DENZIN, L. K., HAMMOND, C., DRAKE, J. R., AMIGORENA, S., CRESSWELL, P., AND MELLMAN, I. 1996. HLA-DM is localized to conventional and unconventional MHC class II-containing endocytic compartments. Immunity 4, 229-239.
25. REINER, S. L., WANG, Z. E., HATAM, F., SCOTT, P., AND LOCKSLEY, R. M. 1993. TH1 and TH2 cell antigen receptors in experimental leishmaniasis. Science 259, 1457-1460.
26. + T cells during initiation of infection. Journal of Experimental Medicine 179, 447-456.
27. REINER, S. L., AND LOCKSLEY, R. M. 1995. The regulation of immunity to Leishmania major. Annual Review of Immunology 13, 151-177.
28. SADICK, M. D., LOCKSLEY, R. M., TUBBS, C., AND RAFF, H. V. 1986. Murine cutaneous leishmaniasis: Resistance correlates with the capacity to generate interferon-γ in response to leishmania antigens in vitro. Journal of Immunology 136, 655-661.
29. SADICK, M. D., HEINZEL, F. P., SHIGEKANE, V. M., FISHER, W. L., AND LOCKSLEY, R. M. 1987. Cellular and humoral immunity to Leishmania major in genetically susceptible mice after in vivo depletion of L3T4+ T cells. Journal of Immunology 139, 1303-1309.
30. SADICK, M. D., HEINZEL, F. P., HOLADAY, B. J., PU, R. T., DAWKINS, R. S., AND LOCKSLEY, R. M. 1990. Cure of murine leishmaniasis with anti-interleukin-4 monoclonal antibody. Journal of Experimental Medicine 171, 115-127.
31. SATOSKAR, A., BLUETHMANN, H., AND ALEXANDER, J. 1995. Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection. Infection and Immunity 63, 4894-4899.
32. SWAIN, S. L. 1994. Generation and in vivo persistence of polarized Th1 and Th2 memory cells. Immunity 1, 543-552.
33. TITUS, R. G., CEREDIG, R., CEROTTINI, J.-C., AND LOUIS, J. A. 1985. Therapeutic effect of anti-L3T4 monoclonal antibody GK1.5 on cutaneous leishmaniasis in genetically susceptible BALB/c mice. Journal of Immunology 135, 2108-2114.
34. WANG, Z. E., REINER, S. L., ZHENG, S., DALTON, D. K., AND LOCKSLEY, R. M. 1994a. CD4+ effector cells default to the Th2 pathway in interferon gamma-deficient mice infected with Leishmania major. Journal of Experimental Medicine 179, 1367-1371.
35. WANG, Z. E., ZHENG, S., CORRY, D. B., DALTON, D. K., SEDER, R. A., REINER, S. L., AND LOCKSLEY, R. M. 1994b. Interferon gamma-independent effects of interleukin 12 administered during acute or established infection due to Leishmania major. Proceedings of the National Academy of Sciences USA 91, 12932-12936.
36. WEI, X. Q., CHARLES, I. G., SMITH, A., URE, J., FENG, G. J., HUANG, F. P., XU, D., MULLER, W., MONCADA, S., AND LIEW, F. Y. 1995. Altered immune responses in mice lacking inducible nitric oxide synthase. Nature 375, 408-411.